In China, legal reforms are being given significant importance to align the pharmaceutical sector with modern requirements and to further strengthen the protection of public health. Improvements in regulations related to the research, production, sale, and supervision of medicines are considered essential not only for the development of the pharmaceutical industry but also for ensuring the supply of safe and high-quality medicines to the public. In this context, the Chinese government has introduced comprehensive amendments to laws governing drug administration. The aim is to encourage innovation, strengthen the regulation of online sales, and tighten supervision related to drug safety.
In this regard, revised regulations for the implementation of the Drug Administration Law have been issued through a State Council decree by Chinese Premier Li Qiang. These regulations consist of nine chapters and 89 articles, and they will come into effect on May 15. Through these amendments, efforts have been made to make the existing system more transparent, efficient, and aligned with modern standards.
A central focus of the revised regulations is the system for drug research and registration. The document highlights a clinical value-oriented approach to drug development, emphasizing the encouragement of innovation in new drug research and the promotion of their medical application. The purpose of this initiative is to ensure that new medicines address real clinical needs and prove effective in treating patients.
The regulations also clarify requirements related to the management of clinical trials, while introducing fast-track evaluation and approval procedures for bringing medicines to the market. Additionally, clear procedures have been established for drug re-registration and for converting prescription medicines into over-the-counter drugs.
To promote pharmaceutical innovation, the revised laws provide special market protection for medicines developed specifically for children and for the treatment of rare diseases. Furthermore, provisions for data protection have been included for drugs containing new chemical entities, ensuring that the interests of companies investing in research and development are safeguarded.
Discipline in the production sector has also been strengthened. In particular, administrative requirements related to the production and sale of decoction pieces and granules of traditional Chinese medicines have been further clarified to maintain quality standards and provide safe products to consumers.
Special attention has also been given to improving supervision over the online sale of medicines. Under these regulations, the responsibilities of third-party e-commerce platforms have been expanded to prevent the sale of substandard or illegal medicines. The objective is to make the process of selling medicines through digital platforms safer and more reliable.
Medical institutions have also been encouraged to prepare specialized medicines for children, enabling them to better meet pediatric medical needs. In addition, to strengthen the monitoring system related to drug safety, detailed procedures have been outlined for inspection, sampling, and testing. If any party raises objections to testing results, provisions have been made for requesting re-testing, while strict legal liabilities have been established for violations.
The revised regulations on drug administration reflect China’s efforts to make its pharmaceutical sector more organized, safe, and modern. By encouraging research and innovation, improving the supervision of online drug sales, and implementing strict safety measures, the goal is to strengthen public health protection. With the implementation of these reforms, it is expected that the availability, quality, and safety of medicines will improve further and that the pharmaceutical industry will move toward sustainable growth.
0 Comments